Oxford Nanopore Technologies plc and Biomérieux SA launched Ampore-TB, a research use only test that can rapidly detect mutations linked to antimicrobial resistance in tuberculosis. With multidrug-resistant TB affecting an estimated 400,000 people annually and increasing risks of morbidity and mortality, this assay could help with earlier diagnosis of drug resistance in patients.
We all look different to HIV, a virus that destroys the immune system. The defensive cells record every interaction with foreign agents, infections from viruses and bacteria, but also with mechanisms occurring within the body, such as microbiome metabolism, the effects of aging, or the development of diseases. At a preconference session at the 13th IAS Conference on HIV Science (IAS 2025), scientists explained the interactions of different microorganisms with HIV.
Antibiotics specialist Bioversys AG has sealed a potential CHF529 million (US$667.5 million) deal with Shionogi Co. Ltd., in which they will work together on novel ansamycins for treating multidrug-resistant lung infections caused by non-tuberculous mycobacteria.
Antibiotics specialist Bioversys AG has sealed a potential CHF529 million (US$667.5 million) deal with Shionogi Co. Ltd., in which they will work together on novel ansamycins for treating multidrug-resistant lung infections caused by non-tuberculous mycobacteria.
Antibiotics specialist Bioversys AG has sealed a potential CHF529 million (US$667.5 million) deal with Shionogi Co. Ltd., in which they will work together on novel ansamycins for treating multidrug-resistant lung infections caused by non-tuberculous mycobacteria.
Centre Hospitalier Regional Universitaire de Lille, Centre National de la Recherche Scientifique, INSERM, Institut Pasteur de Lille and the University of Lille have prepared and tested new tricyclic spirolactam compounds reported to be useful for the treatment of tuberculosis.
New vaccines to control tuberculosis (TB) are urgently needed to fight the global burden of the disease, the increase of resistant strains and the lack of effective vaccines to prevent latent TB infections.
Professor Alexander Star and researchers from the University of Pittsburgh have filed for protection of their development of a rapid, affordable, and reliable tuberculosis diagnostic tool.
The Council of Scientific and Industrial Research (India) has synthesized new benzo[de]isoquinoline-1,3-dione-based fluorophore probes acting as decaprenylphosphoryl-β-D-ribose oxidase (DprE1) (M. tuberculosis) inhibitors reported to be useful for the diagnosis and treatment of tuberculosis.
